The fluorescence polarization immunoassay developed to detect and quantify antibodies against SARS-CoV-2 (IMAGE)
Caption
The fluorescence polarization immunoassay developed to detect and quantify antibodies against SARS-CoV-2. If present in a serum sample, antibodies against the SARS-CoV-2 virus will bind to fluorescently-labelled recombinant SARS-CoV-2 spike proteins (F-RBD); the antibody-bound proteins emit polarized light, which is measured by a fluorescence polarization analyzer (Keine Nishiyama, et al. Biosensors and Bioelectronics. June 5, 2021).
Credit
Keine Nishiyama, et al. Biosensors and Bioelectronics. June 5, 2021
Usage Restrictions
This image is copyrighted but may be used to report this press release, if credited as instructed.
License
Licensed content